Articles tagged with Breast Cancer Cells
A study has identified a molecular signature that drives the growth and survival of triple negative breast cancer cells. The research reveals that high levels of Myc protein and low levels of TXNIP correlate with poor patient outcomes.
A Yale University-led team has compiled sophisticated data on the signaling networks directing highly invasive cancer cells. They found that breast cancer cells prioritize certain cues in the presence of others and can switch their migration mode depending on what they see from the environment.
A previously known gene has been found to act as a tumour suppressor by regulating accurate chromosome segregation. Reduced expression of the glucocorticoid receptor is associated with certain cancer cell types and malignant progression.
Breast cancer cells' growth is inhibited by a combination of estradiol and tumor necrosis factor alpha, improving clinical outcomes for some subtypes. The altered gene expression patterns can be used as biomarkers to determine risk and therapy response.
Australian researchers found a gene ID4 driving the most aggressive form of triple-negative breast cancer. The discovery shows that switching off ID4 may 'tame' these cancers, making them more responsive to existing treatments. Researchers plan to further study how to block the gene and test its potential in mice and humans.
Researchers have discovered a way to enhance chemotherapy's impact by inhibiting the cellular quality-control mechanism NMD, which helps breast cancer cells survive. This strategy primes cells for apoptosis and increases cell death rates.
Researchers discovered that saccharin binds to and deactivates carbonic anhydrase IX, a protein found in some aggressive cancers. This finding opens up the potential to develop novel anti-cancer drugs derived from common condiments.
Researchers at Georgetown University Medical Center have discovered a cellular pathway that controls organ size, which is also related to cancer cell behavior. High-density cells activated the 'Hippo' molecular pathway, while low-density cells did not engage with it, leading to differences in invasion and growth.
Researchers at the University of Arizona discovered how cells know to rush to a wound and heal it, shedding light on mechanisms of cell migration. They found that biomechanical stress and biochemical signaling orchestrate this process, which can be regulated and manipulated to create new tissues.
The Wistar Institute has received a $1.1 million grant from the Jayne Koskinas Ted Giovanis Foundation to support the work of three scientists researching metastatic breast cancer. The researchers aim to develop novel targeted therapies by understanding the pathways essential to breast cancer cells.
A study by the Institute of Cancer Research found that breast cancer cells with a 'mesenchymal-like' shape are more sensitive to inflammatory signals, which could be harnessed to treat cancer. The researchers used robotic microscopy and automated algorithms to measure the shape of hundreds of thousands of different breast cancer cells.
Researchers at the Montreal Neurological Institute and Hospital have discovered a new mechanism driving cancer cell metastasis, focusing attention on the biological role of DENND2B protein. The study highlights Rab13 as an enzyme promoting cell migration in cancer cells.
Researchers developed a new test analyzing 'immune hotspots' to predict breast cancer survival. The test uses statistical software to track the immune system's reaction to tumors, identifying those who need intensive treatment.
A new laboratory test, called Dynamic BH3 Profiling, can predict which cancer treatment will be most effective against a particular type of cancer within less than 24 hours. The test measures how vigorously tumor cells respond to different cancer drugs and has been shown to consistently predict the best treatment in clinical trials.
For the first time, researchers have visualized the molecular machine made up of the estrogen receptor, its coactivator SRC-3, another coactivator called p300, and DNA. This 3-D image revealed the spatial relationships among these molecules, suggesting how the receptor recruits the co-activators and activates genes.
A new study published in Molecular Cancer Therapeutics shows that a low percentage of androgen-receptor-positive cells in triple-negative breast cancer cells can benefit from anti-androgen therapies. This finding may lead to a larger pool of patients eligible for targeted cancer therapy.
Researchers at MD Anderson Cancer Center found that targeting pericytes and angiopoietin-2 signaling may reduce breast cancer tumor growth and metastasis. The study suggests a potential new therapeutic approach for metastatic breast cancer.
A study published in International Journal of Molecular Sciences shows that lithocholic acid, a bile acid produced in the liver, is effective in killing cancer cells and delaying aging. The findings have implications for slowing down breast and prostate cancer development.
Researchers from Brigham and Women's Hospital discovered that targeting cancer cells immediately after chemotherapy can make them more vulnerable to treatment. The 'one-two punch' approach involves administering two drugs simultaneously or sequentially, increasing the effectiveness of cancer therapy.
A new study explains how a protein that suppresses tumors can also promote metastasis in breast cancer cells. Researchers found that 14-3-3 zeta destabilizes key proteins p53 and GLi2, switching off TGF-β's tumor-suppressing abilities while promoting cancer spread.
Researchers at NYU Langone Health have discovered a new pathway to slow down tumor growth in cancers with BRCA1 and BRCA2 genetic mutations. By inhibiting the action of polymerase theta enzyme, cancer cell growth can be cut by more than half.
A team of scientists from Georgetown University and Virginia Tech developed a mathematical model to understand breast cancer cell decisions, revealing a key molecular component that determines resistance to antiestrogen therapy. The study found that interferon regulatory factor-1 (IRF1) promotes resistance to antiestrogens.
Researchers discovered that Twist1, a developmental regulator, primes cells for stem-cell-like properties when activated transiently. This leads to cellular plasticity and regenerative potential. Conversely, chronic Twist1 activity promotes invasive, non-proliferative phenotypes in tumor cells.
Researchers have discovered a novel breast cancer gene called BCL11A that drives the development and progression of triple-negative breast cancer. The study found that BCL11A is active in approximately eight out of ten patients with basal-like breast cancer, and its activity is associated with a more advanced grade of tumour.
A recent study by researchers at Michigan Medicine has uncovered a key gene involved in regulating TGF-beta receptor, explaining the paradox of cancer-promoting proteins. The identified gene, Bub1, was shown to bind to the TGF-beta receptor and promote aggressive cell growth.
A new instrument called BioP3 allows assembly of larger structures from small living microtissue components, potentially making whole organs like livers or kidneys. The device uses pre-assembled living building parts with functional shapes and a thousand times more cells per part.
Breast cancer cells can spread throughout the body when they overexpress the gene SNAIL, which helps them break free from the primary tumor and become more mobile. This unique blend of microarray analysis and characterization of physical changes in breast cancer cells could aid the search for ways to block or slow metastasis.
Researchers will use deep genome sequencing and computer modeling to search for abnormalities in mRNA methylation, a newly discovered epigenetic process linked to diseases like cancer. The study aims to shed new light on the role of mRNA methylation in breast cancer.
Researchers at MIT have identified a link between Musashi proteins and the regulation of cancer cell proliferation. The study found that these RNA-binding proteins can force cells into an epithelial state associated with increased growth, making them a promising target for diagnostic markers and potential treatments.
UT Southwestern Medical Center researchers have identified a cell signaling mechanism that plays a crucial role in brain cancer growth and may provide a new therapeutic target. Non-canonical epidermal growth factor receptor (EGFR) signaling is highly active in glioblastomas, making tumor cells more resistant to chemotherapy treatment.
Dr. Jane Holland's study identified the main driver of basal breast cancer's aggressiveness and targeted treatments to combat it. Her work aims to test inhibitors in human breast cancer tissue, potentially leading to new and effective treatments.
A University of Colorado Cancer Center study reveals that triple-negative breast cancer cells process tryptophan to promote survival while detached, allowing them to metastasize. The kynurenine pathway, specifically the enzyme TDO2, plays a key role in degrading tryptophan and evading anoikis.
A team of scientists at the University of Leicester has identified novel markers to detect senescent cells, which are associated with aging. These markers have shown promise in predicting increased survival in certain types of cancer, particularly breast cancer.
Researchers at Mount Sinai Hospital discovered that bisphosphonates block abnormal growth signals passed through the human EGF receptors, which drive some tumors. The study suggests that bisphosphonates could be used to prevent or treat lung, breast, and colon cancers.
Researchers have found that specific cells are required for the spread of breast cancer, which could lead to new anti-cancer therapies and improve predictive tests. The study combined tumor cells from patients with breast cancer with laboratory models and found a correlation between high MenaINV levels and metastasis.
Researchers have identified a gene, MACROD2, whose presence may explain why some breast cancers are resistant to tamoxifen. The study found that MACROD2 overexpression was present in the majority of metastases in patients with tamoxifen-resistant tumors.
Researchers have developed novel nanoparticle designs that detect and destroy cancer cells using photo-thermal therapy, detecting tumors early and killing them simultaneously. The nanoparticles target specific proteins on cancer cells, releasing heat that burns the abnormal cells without harming normal ones.
Scientists at Northwestern University have developed a genetic-based tool called NanoFlare that can detect live circulating tumor cells in the bloodstream. The technology has the potential to improve diagnosis and treatment of breast cancer by providing a more accurate and personalized approach.
Researchers from Berkeley Lab have developed a new method to create immortal human mammary epithelial cells with normal genomes. This breakthrough could facilitate the examination of cell immortalization as it occurs in cancer development and potentially lead to new therapeutic approaches.
Researchers found that eribulin improves overall survival of women with metastatic triple negative breast cancer and HER2 negative breast cancer by nearly five months and two months respectively. Eribulin, originally developed from sea sponges, is a microtubule inhibitor that stops cancer cells from separating into new cells.
Synthetic lethality harnesses genetic differences between tumor cells and normal cells to minimize side effects on normal cells, while maximizing drug effects on cancer cells. This approach has shown promising results in treating breast cancer patients with BRCA1 and BRCA2 mutations.
Researchers at the University of Utah have discovered that cancers select against a protein complex called the mitochondrial pyruvate carrier (MPC), which counteracts the Warburg effect and supports uncontrolled growth in cancer. Re-introducing MPC into colon cancer cells impairs several properties of cancer, including growth.
Researchers at Virginia Tech developed mathematical models to predict cell transitions, gaining new understanding of transforming growth factor's role in EMT. The study confirms a sequential bistable switch mechanism for EMT, providing conclusive experimental proof for theoretical models.
Ludwig researchers find ASPP2 acts as a molecular switch to regulate EMT and MET, crucial processes in cancer progression. Poor ASPP2 expression correlates with lower patient survival rates in liver and breast tumors.
Research at Beth Israel Deaconess Medical Center identified an unexpected link between the transcription factor FOXP2 and metastatic colonization of breast cancer. Silencing FOXP2 enables breast cancer cells to acquire malignant traits, facilitating their survival and proliferation.
A novel methodology for investigation using modern mass spectrometry has been developed to investigate tumour-promoting activities of breast fibroblasts. This allows for the direct determination of undesirable cell activities in cancer-associated fibroblasts, which may promote tumour growth.
Researchers at the Salk Institute have discovered a mechanism for cancer cells to become resistant to chemotherapy, which may lead to a new approach to treating cancer. The study found that variations in breast cancer cells' RNA enable the cancer to evolve and adapt more quickly than previously thought.
A new study by University of California, San Francisco researchers has discovered a rare population of immune cells associated with less severe cancer outcomes in humans. These 'good' cells, known as antigen-presenting CD103+ dendritic cells, are found in most tumors and may hold therapeutic potential.
A team of researchers from InSilico Medicine has successfully mapped the molecular pathway for myeloid-derived suppressor cell (MDSC) cancer progression. The study identifies several proliferation and invasion-related pathways that are key to MDSC's immune-suppressive effects, opening up new avenues for therapy targeting these cells.
Researchers at the University of Michigan have developed a new approach to discovering potential cancer treatments, replicating the native environment of cancer cells. They identified an antibody, 4C3, that stops breast cancer tumor growth in animal models and are investigating its potential as a treatment for human patients.
Researchers found that estrogen pre-activates the unfolded-protein response (UPR), a pathway that prepares cells to divide and grow. UPR activation is linked to cell proliferation and poor survival in estrogen-receptor-positive breast cancer, making it a potential prognostic marker.
Scientists have discovered a unique biochemical connection between cell membranes and mitochondria, regulating cellular energy production. This finding has implications for understanding diseases linked to mitochondrial dysfunction, including cancer and neurodegenerative disorders.
Researchers at Johns Hopkins Medicine discover that tumor cells can spread through lymphatic vessels by releasing signaling molecules, which attract and facilitate the growth of new blood vessels. The HIV drug maraviroc blocks these signals, preventing breast cancer metastasis when combined with a VEGF-blocking drug.
Researchers at Massachusetts General Hospital found that CTC clusters are associated with poor prognosis and metastatic potential. The presence of CTC clusters in the blood of cancer patients may identify a novel target for therapy.
Male fruit flies use exosomes to reprogram female cells, making them less inclined to remate. The findings suggest that BMP signaling plays a role in regulating female behavior and may be involved in human cancers of tissues that secrete exosomes.
Researchers discovered that breast cancer cells exploit a signaling pathway used by normal mammary stem cells during pregnancy to produce faster-growing, more aggressive tumors. This connection may contribute to the increased short-term risk of highly aggressive breast cancers following each pregnancy.
Researchers have completed the largest cancer genetic analysis ever conducted, revealing a new way of classifying cancers. The study found that one in 10 cancers would be classified differently using this new approach, which could lead to better treatment options for patients.
Researchers analyzed over 3500 tumors using multiple genomic platforms, revealing that cancers are more likely to be molecularly and genetically similar based on their cell type. The study proposes a new classification system that could lead to personalized cancer treatment and eligibility for novel therapeutics.
A team of researchers found that healthy breast cells can differentiate into various cell types similar to those seen in metaplastic carcinoma, a type of triple-negative breast cancer. This discovery challenges the traditional understanding of terminal differentiation and suggests that mature cells may retain some flexibility.
Researchers found that HSF1 activates a transcriptional program in both cancer cells and stromal cells, fueling malignant processes. HSF1 activation is associated with poor patient outcomes in breast and lung cancers, making it a potential biomarker for predicting tumor progression.